Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Financial Advocates Investment Management

Financial Advocates Investment Management grew its stake in shares of Novo Nordisk A/S (NYSE:NVOGet Rating) by 24.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,419 shares of the company’s stock after acquiring an additional 1,469 shares during the quarter. Financial Advocates Investment Management’s holdings in Novo Nordisk A/S were worth $826,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. American Century Companies Inc. increased its holdings in Novo Nordisk A/S by 15.4% in the 1st quarter. American Century Companies Inc. now owns 110,941 shares of the company’s stock worth $12,320,000 after buying an additional 14,816 shares during the period. Cetera Advisor Networks LLC increased its holdings in Novo Nordisk A/S by 22.8% in the 1st quarter. Cetera Advisor Networks LLC now owns 20,220 shares of the company’s stock worth $2,245,000 after buying an additional 3,753 shares during the period. First Horizon Advisors Inc. increased its holdings in Novo Nordisk A/S by 575.7% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,007 shares of the company’s stock worth $335,000 after buying an additional 2,562 shares during the period. Kestra Private Wealth Services LLC increased its holdings in Novo Nordisk A/S by 4.1% in the 1st quarter. Kestra Private Wealth Services LLC now owns 9,879 shares of the company’s stock worth $1,097,000 after buying an additional 388 shares during the period. Finally, ARGI Investment Services LLC acquired a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $238,000. Institutional investors and hedge funds own 6.62% of the company’s stock.

Novo Nordisk A/S Trading Up 2.1 %

Shares of NYSE:NVO opened at $117.83 on Thursday. Novo Nordisk A/S has a 1 year low of $91.51 and a 1 year high of $122.16. The firm has a market capitalization of $266.65 billion, a price-to-earnings ratio of 34.96, a price-to-earnings-growth ratio of 1.84 and a beta of 0.51. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.92 and a quick ratio of 0.74. The business’s 50 day moving average price is $106.54 and its 200-day moving average price is $107.93.

Analyst Ratings Changes

A number of brokerages have recently commented on NVO. StockNews.com began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Credit Suisse Group raised their price objective on shares of Novo Nordisk A/S from 820.00 to 860.00 in a research note on Friday, November 4th. Barclays raised their price objective on shares of Novo Nordisk A/S from 825.00 to 850.00 and gave the stock an “overweight” rating in a research note on Friday, October 14th. Finally, Oddo Bhf raised shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Thursday, September 29th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $717.14.

Novo Nordisk A/S Company Profile

(Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.